期刊文献+

^99Tc^m-MIBI显像用于分化型甲状腺癌复发与P—gp表达的关系研究 被引量:3

Relationship between ^99Tc^m-MIBI imaging and P-gp expression in patients with recurrent differential thyroid carcinoma
原文传递
导出
摘要 目的探讨分化型甲状腺癌(DTC)手术及^131Ⅰ清除剩余甲状腺组织(清甲)后复发时^99Tc^m-甲氧基异丁基异腈(MIBI)显像的特点及耐药蛋白(P-糖蛋白,P—gp)的表达。方法经手术病理检查确诊为DTC、清甲治疗后患者173例,术前均行^99Tc^m-MIBI双时相甲状腺局部静态显像,图像由3位有经验的核医学科医师集体阅片,计算^99Tc^m-MIBI显像早期(10min)、延迟(120min)肿瘤/正常组织放射性(T/NT)比值及洗脱率,术后4~6周行清甲。3年内复发9例为复发组,单纯随机抽样法选择未复发病例9例为无复发组。选取术后癌组织保存标本,采用免疫组织化学法及反转录-聚合酶链反应(RT-PCR)技术检测P—gp的表达。统计学处理采用SPSS10.0软件,行t检验及Spearman秩相关分析。结果DTC复发组早期、延迟相T/NT比值及洗脱率分别为1.18±0.28,1.16±0.24和(17.00±2.91)%,无复发组分别为1.54±0.26,1.65±0.26和(7.00±3.21)%,差异均有统计学意义(t=2.835,4.152,6.924,P均〈0.01);DTC组织中P—gp的阳性细胞数比率复发组为(43.00±8.21)%,明显高于无复发组的(26.00±6.91)%(t=4.753,P〈0.01),不同病理类型间阳性细胞数比率差异无统计学意义(t=0.176,P〉0.05);DTC组织中P—gp的基因表达量复发组为0.60±0.12,明显高于无复发组的0.31±0.19(t=3.871,P〈0.01),不同病理类型DTC的P—gp基因表达量差异无统计学意义(t=0.337,P〉0.05)。免疫组织化学及RT—PCR结果均提示:DTC患者癌组织中的P—gp表达与^99Tc^m-MIBI显像洗脱率之间均存在直线正相关(r=0.84和0.79,P均〈0.05)。结论^99Tc^m-MIBI显像早期、延迟T/NT比值及洗脱率与DTC清甲后复发关系密切,DTC原发灶清除^99Tc^m-MIBI的能力可在体反映P—gp的活性,原发灶^99Tc^m-MIBI的洗脱率可以预测其术后复发。 Objective The aim of this study was to evaluate the relationship between ^99Tc^m-methoxyisobutylisonitrile (MIBI) imaging and P-glycoprotein (P-gp) expression in patient with recurrent differentiated thyroid carcinoma (DTC) after primary definitive thyroidectomy and adjuvant ^131 Ⅰ ablation after operation. Methods A total of 173 pathologically confirmed DTC patients were included. All had twophase ^99Tc^m-MIBI static imaging preoperatively. Both early ( 10 min after intravenous injection) and delayed (120 min after intravenous injection) ^99Tc^m-MIBI tumor/non-tumor (T/NT) ratios and wash-out rates were calculated. Imaging results were analyzed by three experienced nuclear medicine physicians. At the time of follow-up (three years after diagnosis), nine (5.20%) had local tumor recurrence. Nine non-recurrent disease patients were randomized selected as controls. The postoperative carcinoma tissue specimens were obtained to detect P-gp expression through immunohistochemical staining and RT-PCR technique. T test and Spearman correlation were done with SPSS 10.0. Results In recurrent group, the early and late T/NT ra- tios and wash-out rates were 1.18 ±0.28, 1.16 ± 0.24, and ( 17.00 ± 2.91 ) %. In non-recurrent group, the early and late T/NT ratios and wash-out rates were 1.54 ±0.26, 1.65 ±0.26, and (7.00 ±3.21) %. Statistically higher P-gp positive cell number and P-gp gene expression were noted in recurrent than in nonrecurrent groups [ (43.00 ± 8.21)% vs (26. 00 ±6.91)%, t =4. 753, P 〈0.01 and 0.60 ± 0.12 vs 0. 31 ±0.19, t = 3. 871, P 〈 0.01 ). Moreover, positive correlation was noted between P-gp expression and 99Tcm-MIBI wash-out rate among DTC patients ( r = 0.84, P 〈 0.05 and r = 0.79, P 〈 0.05). Conclusions P-gp expression was positively correlated with ^99Tc^m-MIBI wash-out rate among DTC patients and was significantly higher in recurrent than in non-recurrent groups, which might be due to higher P-gp positive cell number in recurrent than in non-recurrent groups.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2008年第6期393-396,共4页 Chinese Journal of Nuclear Medicine
关键词 甲状腺肿瘤 肿瘤复发 局部 糖蛋白类 放射性核素显像 MIBI Thyroid neoplasms Neoplasm recurrence, local Glycoproteins Radionuclide imaging MIBI
  • 相关文献

参考文献13

  • 1Femandes JK, Day TA, Richardson MS, et al. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol, 2005, 6: 47-57.
  • 2Sukhai M, Yong A, Pak A, et al. Decreased expression of P-glycoprotein in interleukin-lbeta and interleukin-6 treated rat hepatocytes. Inflamm Res, 2001, 50: 362-370.
  • 3Moretti JL, Duran Cordobes M, Starzec A, et al. Involvement of glutathione in loss of ^99Tc^m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nuel Med, 1998, 39: 1214-1223.
  • 4戴皓洁,任凌.^(99m)Tc-MIBI甲状腺显像半定量分析鉴别甲状腺结节的价值[J].中国医学影像学杂志,2003,11(4):275-277. 被引量:15
  • 5Zhou J, Higashi K, Ueda Y, et al. Expression of muhidrug resistance protein and messenger RNA correlate with ^99Tc^m-MIBI imaging in patients with lung cancer. J Nucl Med, 2001, 42: 1476-1483.
  • 6Moretti JL, Hauet N, Caglar M, et al. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging, 2005, 32: 836-842.
  • 7Mankoff DA, Dunnwald LK, Gralow JR, et al. ^99Tc^m-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol, 2002, 29: 719-727.
  • 8Yang A, Xue J, Li X, et al. Experimental and clinical observations of ^99Tc^m-MIBI uptake correlate with P-glyeoprotein expression in lung cancer. Nucl Med Commun, 2007, 28 : 696-703.
  • 9Nagamachi S, Jinnouchi S, Nabeshima K, et al. The correlation between ^99Tc^m-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma-a comparative study with ^201Tl. Neuroradiology, 2001, 43: 1023-1030.
  • 10Choi WW, Lewis MM, Lawson D, et al. Angiogenie and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol, 2005, 18: 143-152.

二级参考文献14

  • 1Filipits M, Suchomel RW, Dekan G, et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res, 1996, 2:1231-1237.
  • 2Moretti JL, Duran Cordobes M, Starzec A, et al. Involvement of glutathione in loss of ^99Tc^m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Med, 1998, 39:1214-1218.
  • 3Del VS, Ciarmiello A, Salvatore M. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm, 2000, 15:327-337.
  • 4Kostakoglu L, Elahi N, Kiratli P, et al. Clinical validation of the influence of p-glycoprotein on ^99Tc^m-sestamibi uptake in malignant tumors. J Nucl Med, 1997, 38: 1003-1008.
  • 5Silvana DV, Andrea C, Leonardo P, et al. Fractional retention of ^99Tc^m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med, 1997, 38: 1348-1351.
  • 6Kostakoglu L, Ruacan S, Ergun E, et al. Influence of heterogeneity of P-glycoprotein expression on ^99Tc^m-MIBI uptake in breast cancer. J Nucl Med, 1998, 39: 1021-1026.
  • 7Maini CL, Tofani A, Sciuto R, et al. ^99Tc^m-MIBI scintigTaphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med, 1997, 38: 1546-1551.
  • 8Piwnica-Worms D, Vallabhaneni V, Rao VV, et al. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry, 1995, 34: 12210-12220.
  • 9Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-gp with an organotechnetium complex. Cancer Res, 1993, 53: 977-984.
  • 10Hendrikse NH, Franssen EJ, Graaf WT, et al. ^99Tc^m-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer, 1998, 77: 353-358.

共引文献19

同被引文献30

  • 1胡永成.骨肉瘤化疗效果的影像学评价[J].中华骨科杂志,2004,24(9):569-571. 被引量:4
  • 2邹德环,莫耀溥,余立群,李竹,焦晓凤,周秀卿.甲状腺^(99m)Tc-MIBI显像对甲状腺癌的诊断价值[J].中华核医学杂志,1995,15(3):164-166. 被引量:38
  • 3林开文,刘保平,程兵.乳腺癌^(99)Tc^m-MIBI显像与P-gp、MRP表达的关系[J].中华核医学杂志,2005,25(5):288-290. 被引量:6
  • 4Bacci G,Longhi A,Versari M,et al.Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy:15-year experience in 789 patients treated at a single institution.Cancer,2006,106:1154-1161.
  • 5Rosen G,Caparros B,Huvos AG,et al.Preoperative chemotherapy for osteogenic sarcoma:selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.Cancer,1982,49:1221-1230.
  • 6Huvos AG.Bone tumors:diagnosis,treatment,and prognosis.2nd.Phliladephia:WB senuders,1991:125-140.
  • 7(O)zcan Z,Burak Z,Erin(c) R,et al.Correlation of 99Tcm-sestamibi uptake with blood-pool and osseous phase 99Tcm-MDP uptake in malignant bone and soft-tissue tumours.Nucl Med Commun,2001,22:679-683.
  • 8S(o)derlund V,Larsson SA,Bauer HC,et al.Use of 99Tcm-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy.Eur J Nucl Med,1997,24:511-515.
  • 9Punyaratabandhu T,Wittayawongsaruji S,Rajchadara S,et al.The correlation of 99Tcm-MIBI scintigraphy and histological response in determining the percentage of tumor necrosis in osteosarcoma after preoperative chemotherapy.J Med Assoc Thai,2005,88(3):53-62.
  • 10Burak Z,Moretti JL,Ersoy O,et al.99Tcm-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.J Nucl Med,2003,44:1394-1401.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部